HSD17B4 (hydroxysteroid 17-beta dehydrogenase 4) is a multifunctional enzyme predominantly involved in peroxisomal β‑oxidation of fatty acids and steroid metabolism. Its dysregulation has attracted attention in various cancers.
Breast Cancer
• Expression:
– Some studies have observed altered HSD17B4 expression in breast cancer tissues compared to normal tissues. In certain cohorts, overexpression has been noted, which may affect local steroid metabolism and estrogen synthesis.
• Prognosis:
– Overexpression in some reports has been linked to endocrine resistance and a more aggressive phenotype, suggesting a potential role as a marker of unfavorable prognosis.
Hepatocellular Carcinoma (HCC)
• Expression:
– In liver cancers, HSD17B4 expression may be aberrant. Some studies have reported increased expression compared to non-tumor liver tissues, potentially reflecting metabolic reprogramming in cancer cells.
• Prognosis:
– Elevated HSD17B4 expression in HCC has been associated in certain reports with poor survival outcomes, suggesting its involvement in tumor metabolism and progression.
(Will delete Record if Target field = "Delete") Home